MedPath

the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Ankle

Phase 4
Conditions
Defect of Articular Cartilage
Interventions
Procedure: Microfracture
Device: CartiFill
Registration Number
NCT02519881
Lead Sponsor
Sewon Cellontech Co., Ltd.
Brief Summary

This study was designed to evaluate the efficacy and safety of a modified microfracture using collagen, and to compare them with those of a simple microfracture in patients with cartilage defects in their ankles.

Detailed Description

This study was an open-trial study. Sixty subjects participated in it. The study was explained to the subjects and they voluntarily agreed to participate in it. Their eligibility to participate in the study was checked, and they were randomized either into the simple microfracture group or the modified microfracture group using collagen based on a randomization table. They were asked to follow the guidelines of the investigators during the study and to visit the hospital five times, including for screening. At each visit, the subjects underwent an examination with doctors and MRI to evaluate the efficacy of the procedure. (\*If the subject began the first visit on the screening date, the total number of his or her visits was four.)

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  1. Patients who were 15 years old or older
  2. Patients with cartilage defects in their ankle
  3. Patients with misalignment of their tibia and talus, unstable ligament in their ankle, or bony defects in the lesions of their ankle, and/or who had been treated for alignment
  4. Patients or their representative (for adults), or patients and their parent/guardian (for minors), who agreed to participate in the study and signed the informed consent form
Exclusion Criteria
  1. If patients or their families suffer from or have ever suffered from an autoimmune disease.
  2. Patients who have ever suffered an anaphylactic reaction.
  3. Patients who have ever suffered hypersensitivity to an implant.
  4. Patients with a history of allergy to porcine or bovine protein.
  5. Subjects with inflammatory arthritis, such as rheumatoid and gouty arthritis.
  6. Subjects with autoimmune disease related arthritis.
  7. Subjects who are pregnant and/or breast-feeding and/or plan a pregnancy.
  8. Subjects with tumors.
  9. Subjects who have undergone radiotherapy or chemotherapy within the last 2 years (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
  10. Subjects who are diabetic. (Exception: if the possibility of CartiFillā„¢ treatment is confirmed with doctor's clinical decision, and/or patient's blood glucose level remains within the normal range and/or no other complications by diabetes mellitus.)
  11. Subjects with infections, currently on treatment with antibiotics or antimicrobials (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
  12. Subjects under adrenocorticoid therapy (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
  13. Subjects with psychiatric disorders who are considered inappropriate to participate in this trial by the Principal Investigator.
  14. Patients who have ever suffered contraindications of the used Fibrin sealant. (The major contraindications are as follows: patients with hypersensitivity to aprotinin and those treatments for severe brisk arterial or venous bleeding.)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
modified microfracture using collagenMicrofracturemodified microfracture using collagen (CartiFill) for cartilage defect of ankle
modified microfracture using collagenCartiFillmodified microfracture using collagen (CartiFill) for cartilage defect of ankle
microfractureMicrofracturesimple microfracture for cartilage defect of ankle
Primary Outcome Measures
NameTimeMethod
100mmVAS(visual analogue scale) score12 months after the surgery

The VAS's were evaluated 12 months after the surgery on the affected ankle in the study and control groups.

Secondary Outcome Measures
NameTimeMethod
Change score of 100mmVAS(visual analogue scale)Screening, 6, 12, and 24months after surgery

The difference in the 100mmVAS on the affected ankle at the screening and after 12 months was compared in the study and control group, as were the differences in the 100mmVAS after 6, and 24 months.

Change of Satisfaction evaluation by patientsScreening, 6, 12, and 24months after surgery

The improvements in the affected ankle before and 12 months after the surgery (and six and 24 months after the surgery) were compared in the study and control group.

Change of AOFAS(American orthopaedic foot & ankle society) ScoreScreening, 6, 12, and 24months after surgery

The difference in the AOFAS on the affected ankle at the screening and after 12 months was compared in the study and control group, as were the differences in the AOFAS after 6, and 24 months.

Change of Hannover ScoreScreening, 6, 12, and 24months after surgery

The difference in the Hannover Score on the affected ankle at the screening and after 12 months was compared in the study and control group, as were the differences in the Hannover Score after 6, and 24 months.

Change of Satisfaction evaluation by physician in chargeScreening, 6, 12, and 24months after surgery

The improvements in the affected ankle before and 12 months after the surgery (and six and 24 months after the surgery) were compared in the study and control group.

Change results of Arthroscopy (ICRS(International Cartilage Repair Society))before and 24 months after the surgery

The conditions of the affected ankle before and 24 months after the surgery were recorded and the ICRS's were evaluated in the study and control group.

\* Arthroscopy was performed in up to 10 subjects who signed the consent form.

the result of MRI(mMOCART)24 months after the surgery

The conditions of the affected ankle 24 months after the surgery were recorded and the mMOCART were evaluated in the study and control group.

Trial Locations

Locations (3)

Soon Chun Hyang University Hospital Bucheon

šŸ‡°šŸ‡·

Bucheon, Gyeonggi-do, Korea, Republic of

Eulji general Hospital

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Hallym University Medical Center-Kangnam Sacred Heart Hospital

šŸ‡°šŸ‡·

Seoul, Korea, Republic of

Ā© Copyright 2025. All Rights Reserved by MedPath